| Identification | Back Directory | [Name]
Piperazine, 1-cyclobutyl-4-[4,5-dihydro-1-[[4-(3-thienyl)phenyl]sulfonyl]-1H-imidazol-2-yl]- | [CAS]
1965248-01-4 | [Synonyms]
KDM2B-IN-2
Piperazine, 1-cyclobutyl-4-[4,5-dihydro-1-[[4-(3-thienyl)phenyl]sulfonyl]-1H-imidazol-2-yl]- | [Molecular Formula]
C21H26N4O2S2 | [MOL File]
1965248-01-4.mol | [Molecular Weight]
430.59 |
| Chemical Properties | Back Directory | [Boiling point ]
562.0±60.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 31.25 mg/mL (72.57 mM; ultrasonic and heat to 80°C) | [form ]
Solid | [pka]
7.89±0.70(Predicted) | [color ]
White to light brown |
| Hazard Information | Back Directory | [Biological Activity]
KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases research[1]. | [References]
[1]. Brian K. Albrecht, et al. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors. Patent WO2016112251A1. |
|
|